Incidence and treatment of postimplantation syndrome after endovascular repair of infrarenal aortic aneurisms
Incidence and treatment of postimplantation syndrome after endovascular repair of infrarenal aortic aneurisms
复制标题
DOI：
10.1007/s00772-013-1193-x
复制
发表时间：
2013-09-01
期刊：
影响因子：
0.3
通讯作者：
Boeckler, D.
中科院分区：
文献类型：
--
作者：
Bischoff, M. S.;Hafner, S.;Boeckler, D.
为了评价在德国血管外科实践中肾下主动脉瘤（AAA）腔内修复术（EVAR）后植入后综合征（PIS）的作用，从2012年1月至2012年4月，使用标准化问卷调查了124个德国血管外科部门的PIS经验。分类为每年腹主动脉瘤腔内修复术频率、使用的覆膜支架器械、PIS发生率、PIS诊断标准、PIS治疗以及PIS作为腹主动脉瘤腔内修复术后并发症的相关性。可分析的返回率为59.7%（74/124）。在70.2%（52/74）中，腹主动脉瘤腔内修复术的数量为1/1000日元欧元/年。PIS的发病率估计为千分之一欧元，占病例的70.2%（52/74）。所用的诊断临界值为体温a千分之一yenaEuro千分之38.5 A ℃，白色血细胞计数a千分之一yenaEuro千分之12/nl，C反应蛋白水平为50-100 mg/l。采用多种非甾体类抗炎药进行治疗。对于55.4%（41/74）的参与中心，PIS不代表腹主动脉瘤腔内修复术后的相关并发症。非甾体类抗炎药对PIS的治疗不一致，PIS的临床意义尚不清楚。由于缺乏明确的诊断标准，很难确定PIS的确切发病率。由于目前关于PIS病因和发病机制的数据有限，其对长期预后的影响尚不清楚，PIS患者的个体负担需要进一步研究。
To evaluate the role of the postimplantation syndrome (PIS) after endovascular repair (EVAR) of infrarenal aortic aneurysms (AAA) in German vascular surgery practice.From January 2012 to April 2012, a total of 124 German departments for vascular surgery were surveyed regarding their experience with PIS using a standardized questionnaire. Categories were EVAR frequency per year, stent graft devices used, PIS incidence, diagnostic criteria for PIS, treatment of PIS, and relevance of PIS as a complication after EVAR.The analyzable return rate was 59.7 % (74/124). In 70.2 % (52/74), the number of EVAR procedures performed was a parts per thousand yenaEuro parts per thousand 25/year. The incidence of PIS was estimated to occur in a parts per thousand currency signaEuro parts per thousand 20 % of cases by 70.2 % (52/74). The diagnostic cut-off values used were body temperature a parts per thousand yenaEuro parts per thousand 38.5 A degrees C, white blood cell count a parts per thousand yenaEuro parts per thousand 12/nl, and C-reactive protein levels of 50-100 mg/l. A variety of non-steroidal anti-inflammatory drugs were used for treatment. For 55.4 % (41/74) of the participating centers, PIS does not represent a relevant complication after EVAR. PIS is nonuniformly treated with nonsteriodal anti-inflammatory agents.The clinical relevance of PIS is still unclear. The lack of defined diagnostic criteria makes it difficult to determine the exact incidence of PIS. Due to the currently limited data on PIS etiology and pathogenesis, the impact on long-term outcome is unknown and the individual burden of patients suffering PIS requires further research.The English full-text version of this article is available at SpringerLink (under "Supplemental").